Pelvic Metastasis
Conditions
Brief summary
Determine whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure
Detailed description
Primary Objectives 1\. Evaluate whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure Secondary Objectives 1. Evaluate whether the procedure relieves pain 2. Evaluate radiographic stability of the implant 3. Evaluate functional outcome at earlier time points (2 weeks or 6 weeks) and at 6 months and possibly later time points 4. Evaluate reoperation rate and complications
Interventions
PROCEDUREPhotodynamic nails
stab incision is made at the entry site
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a histologically confirmed malignancy from prior biopsy of the primary tumor or a metastatic site. Patients with carcinoma, myeloma, and lymphoma may be included in the study. Patients should have metastatic involvement of the periacetabular region that is visible radiographically. Biopsy of acetabular disease is not required for this study. * Age ≥18 years (Illuminoss is approved only for skeletally mature patients) * Suitable candidate for general anesthesia * Ability to understand and the willingness to sign a written informed consent document. * Able and willing to fill out pre-operative and post-operative functional outcome surveys * Absolute neutrophil count ≥ 1,500/mcL * Platelets ≥ 50,000/mcL
Exclusion criteria
* Patients with uncontrolled intercurrent illness (e.g., recent pneumonia or myocardial infarction that would significantly increase risk of general anesthesia) * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Patients with psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because of the risk of general anesthesia and radiation exposure (fluoroscopy) to the fetus * History of allergic reactions attributed to compounds of similar chemical or biologic composition to dental resins or PET.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 | Through study completion, up to one year |
Countries
United States
Contacts
CONTACTPatrick Lin, MD
PRINCIPAL_INVESTIGATORPatrick Lin, MD
M.D. Anderson Cancer Center
Outcome results
None listed